Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Intensive ART in HIV-Infected Infants
NCT00000872Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of abacavir, nelfinavir, nevirapine, lamivudine, stavudine and 1 more in human immunodeficiency virus infection (HIV) (3 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Antiretroviral activity of ZDV/3TC/NVP, Durability of viral suppression and 4 more. Status: completed.
02
Drugs
abacavirnelfinavirnevirapinelamivudinestavudine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00000872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00000872.